Neuroleptic treatment of schizophrenia is characterized by a delayed and often incomplete response to medication. We will characterize the metabolic adaptation of the brain to neuroleptic intervention for the purpose of identifying factors associated with therapeutic response. We will use Positron Emission Tomography (PET) and the deoxyglucose method to measure the immediate and long-term effects of neuroleptic treatment on regional glucose metabolism. Glucose utilization is the final common path for the bioenergetics of all neurochemical processes. Thus, regardless of the important details of neurotransmitter system activations, the pattern of regional energy utilization should reflect the adaptation of the brain to neuroleptic intervention. For these studies, we will measure regional glucose metabolism in four groups: never-medicated schizophrenics, previously medicated drug-responsive schizophrenics, previously medicated drug-unresponsive schizophrenics, and normal control subjects.
The specific aims of the experiments are: (1) to measure the metabolic consequences of a single neuroleptic dose in never-medicated schizophrenics and normal controls; (2) to measure the long-term metabolic consequences of neuroleptic treatment in never-medicated schizophrenics; (3) to measure the relationship between clinical outcome, metabolic patterns, and plasma homovanillic acid concentration as a function of time in drug-responsive and unresponsive schizophrenics; and (4) to measure the relationship between metabolic patterns and clinical outcome in drug responsive schizophrenics maintained over time at a low plasma level of neuroleptic. By measuring metabolic response to neuroleptic treatment, we hope to provide a new approach to study the pathophysiology of schizophrenia. We expect that new insights, derived from these results, will enable us to develop better diagnosis and treatment of this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH047277-01A1
Application #
3387095
Study Section
Psychopathology and Clinical Biology Research Review Committee (PCB)
Project Start
1991-09-30
Project End
1993-08-31
Budget Start
1991-09-30
Budget End
1992-08-31
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
New York University
Department
Type
Schools of Medicine
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012
Hutchinson, M; Schiffer, W; Joseffer, S et al. (1999) Task-specific deactivation patterns in functional magnetic resonance imaging. Magn Reson Imaging 17:1427-36
Schlosser, R; Brodie, J D; Dewey, S L et al. (1998) Long-term stability of neurotransmitter activity investigated with 11C-raclopride PET. Synapse 28:66-70
Schlosser, R; Hutchinson, M; Joseffer, S et al. (1998) Functional magnetic resonance imaging of human brain activity in a verbal fluency task. J Neurol Neurosurg Psychiatry 64:492-8
Smith, G S; Schloesser, R; Brodie, J D et al. (1998) Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25
Bartlett, E J; Brodie, J D; Simkowitz, P et al. (1998) Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatry 155:337-43
Schloesser, R; Simkowitz, P; Bartlett, E J et al. (1996) The study of neurotransmitter interactions using positron emission tomography and functional coupling. Clin Neuropharmacol 19:371-89
Bartlett, E J; Brodie, J D; Simkowitz, P et al. (1996) Time-dependent effects of a haloperidol challenge on energy metabolism in the normal human brain. Psychiatry Res 60:91-9
Wang, G J; Volkow, N D; Wolf, A P et al. (1994) Intersubject variability of brain glucose metabolic measurements in young normal males. J Nucl Med 35:1457-66
Bartlett, E J; Brodie, J D; Simkowitz, P et al. (1994) Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiatry 151:681-6